| Literature DB >> 24771866 |
Ingemar Björkhem1, Ulf Diczfalusy1, Anita Lövgren-Sandblom1, Lena Starck2, Monica Jonsson3, Keri Tallman4, Henrik Schirmer5, Lilian Bomme Ousager6, Peter J Crick7, Yuqin Wang7, William J Griffiths7, F Peter Guengerich4.
Abstract
A new mechanism for formation of 7-ketocholesterol was recently described involving cytochrome P-450 (CYP)7A1-catalyzed conversion of 7-dehydrocholesterol into 7-ketocholesterol with cholesterol-7,8-epoxide as a side product. Some patients with cerebrotendinous xanthomatosis (CTX) and all patients with Smith-Lemli-Opitz syndrome (SLO) have markedly increased levels of 7-dehydrocholesterol in plasma and tissues. In addition, the former patients have markedly upregulated CYP7A1. We hypothesized that these patients may produce 7-ketocholesterol from 7-dehydrocholesterol with formation of cholesterol-7,8-epoxide as a side product. In accord with this hypothesis, two patients with CTX were found to have increased levels of 7-ketocholesterol and 7-dehydrocholesterol, as well as a significant level of cholesterol-7,8-epoxide. The latter steroid was not detectable in plasma from healthy volunteers. Downregulation of CYP7A1 activity by treatment with chenodeoxycholic acid reduced the levels of 7-ketocholesterol in parallel with decreased levels of 7-dehydrocholesterol and cholesterol-7,8-epoxide. Three patients with SLO were found to have markedly elevated levels of 7-ketocholesterol as well as high levels of cholesterol-7,8-epoxide. The results support the hypothesis that 7-dehydrocholesterol is a precursor to 7-ketocholesterol in SLO and some patients with CTX.Entities:
Keywords: Smith-Lemli-Opitz syndrome; cerebrotendinous xanthomatosis; cholesterol 7,8-epoxide; cytochrome P-450 7A1; liquid chromatography-mass spectrometryn
Mesh:
Substances:
Year: 2014 PMID: 24771866 PMCID: PMC4031947 DOI: 10.1194/jlr.P048603
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922